These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse. Beardsley PM; Shelton KL; Hendrick E; Johnson KW Eur J Pharmacol; 2010 Jul; 637(1-3):102-8. PubMed ID: 20399770 [TBL] [Abstract][Full Text] [Related]
11. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. De La Garza R; Zorick T; Heinzerling KG; Nusinowitz S; London ED; Shoptaw S; Moody DE; Newton TF Pharmacol Biochem Behav; 2009 Nov; 94(1):186-93. PubMed ID: 19698734 [TBL] [Abstract][Full Text] [Related]
12. A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes. Lee N; Pennay A; Hester R; McKetin R; Nielsen S; Ferris J Drug Alcohol Rev; 2013 Jan; 32(1):88-95. PubMed ID: 22630616 [TBL] [Abstract][Full Text] [Related]
13. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Rolan P; Gibbons JA; He L; Chang E; Jones D; Gross MI; Davidson JB; Sanftner LM; Johnson KW Br J Clin Pharmacol; 2008 Dec; 66(6):792-801. PubMed ID: 19032723 [TBL] [Abstract][Full Text] [Related]
14. Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine. Reynolds AR; Strickland JC; Stoops WW; Lile JA; Rush CR Drug Alcohol Depend; 2017 Dec; 181():25-29. PubMed ID: 29028556 [TBL] [Abstract][Full Text] [Related]
15. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial. Rezaei F; Ghaderi E; Mardani R; Hamidi S; Hassanzadeh K Fundam Clin Pharmacol; 2016 Jun; 30(3):282-9. PubMed ID: 26751259 [TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Longo M; Wickes W; Smout M; Harrison S; Cahill S; White JM Addiction; 2010 Jan; 105(1):146-54. PubMed ID: 19839966 [TBL] [Abstract][Full Text] [Related]
17. Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety. Johnson JL; Kwok YH; Sumracki NM; Swift JE; Hutchinson MR; Johnson K; Williams DB; Tuke J; Rolan PE Headache; 2015 Oct; 55(9):1192-208. PubMed ID: 26367865 [TBL] [Abstract][Full Text] [Related]
18. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Johnson BA; Ait-Daoud N; Elkashef AM; Smith EV; Kahn R; Vocci F; Li SH; Bloch DA; Int J Neuropsychopharmacol; 2008 Feb; 11(1):1-14. PubMed ID: 17470315 [TBL] [Abstract][Full Text] [Related]
19. Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose. Li L; Lopez JC; Galloway GP; Baggott MJ; Everhart T; Mendelson J Ther Drug Monit; 2010 Aug; 32(4):504-7. PubMed ID: 20592647 [TBL] [Abstract][Full Text] [Related]
20. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]